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ABSTRACT

Our conceptualization and empirical understanding of the course of depression is
beginning to change. This is largely a result of recent epidemiological and clinical data
that suggest depression has a chronic course for many individuals. Treatment studies for
chronic depression have found that response rates are consistently less robust than in
studies of acute, episodic depression. As is such, investigators have begun to examine
factors that impede treatment response among these patients. One such factor is the
presence of comorbid Axis-II personality disorders. This study examined the moderating
effects of Depressive Personality Disorder (DPD) on treatment outcome among 680
outpatients with chronic depression. Results suggest that DPD did not serve as a
prognostic indicator of worse outcome after 12 weeks of treatment or at last observation
carried forward. This was a secondary analysis of the data presented by Keller and
colleagues (Keller, McCullough, Klein, Arnow, Dunner, & Gelenberg, 2000).
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Introduction
Extensive clinical and epidemiological data has consistently indicated that Major
Depressive Disorder (MDD) is a highly prevalent, often recurrent condition associated
with substantial psychosocial dysfunction, morbidity and mortality (Kessler, McGonagle,
& Zhao, 1994; Wells, Stewart, & Hayes, 1989; Wells, Golding, & Burnam, 1988; Wells,
1985; Coryell, Noyes, & Clancy, 1982). Point prevalence rates registered by the National
Comorbidity Survey (NCS) were estimated at 4.9%, suggesting that over 14 million
people in the United States suffer from MDD at any given time (Kessler et al., 1994).
Moreover, a World Health Organization (WHO) report ranked unipolar major depression
as the leading cause of years lived with disability worldwide in 1990 (Murray & Lopez,
1996). It is estimated that by the year 2020, depression will be the second most disabling
condition in the world below ischaemic heart disease, and the leading cause of disease
burden among women and people in developed countries (Murray & Lopez, 1996).
Perhaps the most salient statistics involve the relationship between depression and
mortality. Fifteen percent of patients who require hospitalization for severe depression
will die by committing suicide (Coryell et al., 1982). Approximately 10% of patients
with MDD who attempt suicide will eventually take their own lives. One study found
that approximately 50% of individuals who committed suicide had a primary diagnosis of
MDD (Barklage, 1991). Taken together, it is strikingly evident that MDD is a serious
health problem.
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MDD has traditionally been conceptualized as an episodic, remitting condition.
However, major epidemiological studies indicate that 3% – 6% of individuals in
community samples have experienced a chronic course of depression (at least 2 years in
duration) (Robins & Regier, 1991). Data from the National Institute of Mental Health
Collaborative Depression Study longitudinal follow-up suggest that over 19% of
depressed patients experienced chronic episodes lasting 2 years or more, and 7% of those
individuals had not recovered after 8 years (Mueller, Keller, & Leon, 1996).
Observations from other large outcome studies including the Zurich Follow-Up Study
(Angst, 1986) and the Medical Outcomes Study (Wells et al., 1989) have helped
reconceptualize our understanding of MDD from that of an episodic illness toward a
disorder that is more chronic in course for many patients. Furthermore, in clinical
settings, chronic depression is commonly seen, with a reported 22%-36% of outpatients
meeting criteria for Dysthymic Disorder (Klein & Santiago, 2003).
Although no uniform definition of chronic depression exists, depression is
broadly regarded as ‘chronic’ when clinically significant symptomatology and functional
impairment extend over several years. Recent attempts to classify chronic depression
using longitudinal course specifiers have led to the description of three different forms in
the DSM-IV: (1) Dysthymic Disorder, (2) Major Depressive Disorder, chronic type, and
(3) recurrent Major Depressive Disorder without full interepisode recovery (American
Psychiatric Association, 2000). Additionally, the term ‘double depression’ is used to
describe Dysthymic Disorder with a superimposed major depressive episode (Keller &
Shapiro, 1982).
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Treatment for Depression: There has been rigorous empirical study over the past
20 years investigating the efficacy of various treatments for MDD. Additionally, the
Department of Health and Human Services Agency for Health Care Policy and Research
(AHCPR) published a comprehensive report outlining the range of treatments available
for patients with MDD (1993). Overall, three common treatment types are available:
medication, psychotherapy, and combination treatment. Response rates to a single
antidepressant medication were found to be 60%-70%, compared to placebo response
rates of 30% (Gitlin, 2002). These figures are somewhat inflated because they exclude
those who fail to complete the clinical trial. Overall, this means that many patients
significantly improve, but it also indicates that some 30%-40% of patients treated with
antidepressants do not get better.
The efficacy of antidepressant medication has been established for the short-term
treatment of chronic depressions by randomized, placebo-controlled clinical trials
(Kocsis, 2003). Medications found to be superior to placebo include tricyclic
antidepressants (TCAs) and serotonin reuptake inhibitors (SSRIs). Unfortunately,
however, the response rates among chronically depressed individuals in such trials are
substantially lower than those reported in studies of acute major depression, which also
demonstrates their refractory nature (Gwirtsman, Blehar, & McCullough, 1997; Khan,
Dager, & Cohen, 1991; Stewart, McGrath, & Quitkin, 1993; Kocsis, Frances, & Voss,
1987). Similarly, placebo response rates among this population are also lower than those
usually seen for acute major depression (Khan et al., 1991; Brown, Dornseif, &
Wernicke, 1988; Fairchild, Rush, & Vasvada, 1986). Eleven controlled trials involving
acute treatment of chronically depressed patients yielded intent-to-treat response rates in
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the range of only 45%-55% (Kocsis, 2003). Moreover, forty percent (40%) of responders
typically did not meet criteria for full remission.
Several studies have also examined the efficacy of targeted psychotherapies for
chronic forms of depression (Markowitz, 1994; Rush & Thase, 1999). Most of these
studies have been open rather than controlled trials, and nearly all of them assessed
psychotherapy as a monotherapy rather than an adjunctive treatment. Cognitivebehavioral therapy (CBT) has been found to have measurable but modest treatment
effects among patients with Dysthymic Disorder or chronic major depression, with a
mean response rate of approximately 31% (Markowitz, 1996). Interpersonal
psychotherapy (IPT) has also been reported to be helpful; however, methodological
limitations, such as small sample size, have compromised the usefulness of these results
(Mason, Markowitz, & Klerman, 1993).
More recently, researchers have begun to investigate the value of combination
treatment. Keller and colleagues designed a large multisite collaborative study to
specifically target chronic depression (Keller, McCullough, Klein, Arnow, Dunner, &
Gelenberg, 2000). The study compared nefazodone alone (up to 600mg/day) to
psychotherapy alone (16 to 20 sessions) to the combination over a 12-week period. Six
hundred and eighty one patients (n=681) with chronic MDD, MDD plus Dysthymic
Disorder (double depression), or recurrent MDD without interepisode recovery were
randomized to one of the three treatment arms. Overall response rates for the intent-totreat sample were 48% for psychotherapy, 48% for nefazodone, and 73% for the
combination. Remission rates were 33% for psychotherapy, 29% for nefazodone, and
48% for the combination. Fifty two percent (52%) of psychotherapy patients, 51% of
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nefazodone patients, and 25% of combination patients were considered to have no
response to treatment. A secondary analysis of this study is the focus of the proposed
investigation.
Despite some evidence for the efficacy of antidepressant medication and
psychotherapy for chronic depression, the overall response and remission rates remain
relatively low, particularly for monotherapy. Moreover, our ability to predict which
patients will respond to any particular treatment, or combination of treatments, remains
elusive.
One potentially important factor influencing treatment response is Axis-II
comorbidity. High rates of co-occurring personality disorders are frequently found in
depressed inpatients and outpatients, with most studies reporting rates from 30%-60%
(Flick, Roy-Byrne, & Cowley, 1993; Shea, Widiger, & Klein, 1992). Importantly, AxisII personality disorders are particularly high for chronic forms of depression, with rates as
high as 85% in some studies (Pepper, Klein, & Anderson, 1995; Markowitz, Moran, &
Kocsis, 1992; Alnnaes & Torgersen, 1991).
A majority of studies of depressed patients found significant evidence that the
presence of a personality disorder is associated with worse outcome (McDermut &
Zimmerman, 1998; Shea et al., 1992; Shea, Pilkonis, & Beckham, 1990). This finding is
fairly consistent across type of treatment involved, and has been replicated in several
patient populations including inpatients, outpatients, those referred from primary care,
and the elderly (Rothschild & Zimmerman, 2002). Some studies have found that cluster
A (paranoid, schizoid, schizotypal) and cluster C (avoidant, dependent, obsessivecompulsive) personality disorders are related to poorer outcome (Greenberg, Craighead,
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& Evans, 1995; Sato, Sakado, & Sato, 1994; Peselow, Fieve, & DiFiglia, 1992) although
some studies have not had this finding (Fava, Bouffides, & Pava, 1994; Newman, Ewing,
& McColl, 2000). Recently, Papakostas and colleagues examined whether the presence
of comorbid Axis I and Axis II disorders predicted clinical response to an open trial of
nortriptyline among patients with treatment-resistant depression (Papakostas, Peterson, &
Farabaugh, 2003). Forty-two percent (42%) of patients responded to nortriptyline;
however, the presence of Avoidant Personality Disorder predicted poorer response to the
drug. The response rate was only 16.7% for patients with Avoidant Personality Disorder
and 48.6% for patients without Avoidant Personality Disorder.
Evidence of the impact of personality on treatment outcome for depression can be
best explained by the pathoplasticity model (Klein, Wonderlick, & Shea, 1993). The
pathoplasticity model views personality as having a direct, causal impact on the
expression of depression after onset. More specifically, this model suggests that there is
a nonetiologic relationship between two psychological disorders, although the presence
of one disorder affects the clinical presentation and/or the course of the second disorder.
In other words, the comorbid disorder affects the presentation of the other disorder, not
the risk for developing the disorder. This includes personality influencing response to
treatment among patients with depression (Klein, Durbin, & Shankman, 2002).
Perhaps owing to its status as an appendix diagnosis in the DSM-IV, the impact of
Depressive Personality Disorder (DPD) has scarcely been studied. The core features of
DPD are excessive, negative, pessimistic beliefs about oneself, others, and the world.
These are persons who characteristically display gloominess, cheerlessness, pessimism,
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brooding, rumination, and dejection. The DSM-IV provisional criteria set for Depressive
Personality Disorder can be found in Table 1.
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Table 1. DSM-IV criteria for Depressive Personality Disorder and Dysthymic Disorder
Depressive Personality Disorder

Dysthymic Disorder

A pervasive pattern of depressive cognitions and
behaviors beginning by early adulthood and present
in a variety of contexts as indicated by five
(or more) of the following:

Depressed mood for most of the
day, for more days than not, as
indicated either by subjective
account or observation by
others, for at least two years.
Presence, while depressed, of
two (or more) of the following:

(1) usual mood is dominated by dejection, gloominess,
cheerlessness, joylessness, unhappiness;

(1) poor appetite or overeating

(2) self-concept centers around beliefs of inadequacy,
worthlessness, and low self-esteem;

(2) insomnia or hypersomnia

(3) is critical, blaming, and derogatory toward self;

(3) low self-esteem

(4) is brooding and given to worry;
difficulty making choices

(4) poor concentration or

(5) is negativistic, critical, and judgmental toward others;

(5) feelings of hopelessness

(6) is pessimistic;
(7) is prone to feeling guilty or remorseful.
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Although there is a dearth of treatment outcome data, several papers have
investigated the role of DPD and its relationship to depressive disorders (Ryder, Bagby,
& Schuller, 2002; Ouimette, Klein, & Pepper, 1996; Huprich, 2001; Klein, 1990). It has
been posited that DPD may represent the characterologic core of depression, particularly
in patients with chronic forms of depression (Ryder et al., 2002). Support for this notion
is provided by recent family-genetic studies (Klein, 1999; Klein, Riso, & Donaldson,
1995). Much of this has been the focus of work done by Klein and colleagues (Klein,
1990; Klein & Miller, 1993). This group has demonstrated an increased rate of mood
disorders among first-degree relatives of patients with DPD. Conversely, there is
evidence of an increased rate of DPD in the relatives of patients with Major Depressive
Disorder (MDD) and early-onset Dysthymic Disorder. In one study, adolescents and
young adult offspring of parents with MDD had significantly higher rates of depressive
personality than offspring of medical and normal controls (Klein, Clark, & Dansky,
1988) More recently, it was found that relatives of patients with Dysthymic Disorder
exhibited a significantly higher rate of depressive personality as compared to the relatives
of normal controls (Klein, 1999).
There has been large debate about whether Depressive Personality Disorder can
be adequately distinguished from Dysthymic Disorder (Hirschfeld & Holzer, 1994; Clark
& Watson, 1999; Bagby & Ryder, 1999; Huprich, 2001). This is because the DSM-IV
diagnostic criteria significantly overlap, leading to questions about whether DPD should
be conceptualized as a distinct entity (Table 1). Although some investigators posit that
DPD cannot adequately be distinguished from Dysthymic Disorder, a field trial by the
DSM-IV Mood Disorders Work Group indicated that many patients meet criteria for
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DPD but not Dysthymic Disorder (Phillips, Hirschfeld, & Shea, 1995; Widiger, 1999).
Conversely, patients with more affective symptoms meet criteria for Dysthymic Disorder
but not DPD. Nevertheless, additional research is needed to differentiate between the
two disorders and to determine whether DPD is best conceptualized as a personality
disorder or an affective disorder.
Given the data on the effects of personality disorders on treatment outcome
among patients with depression and evidence of the validity of DPD, we predicted that
DPD would have a negative impact on treatment response. Thus, the poor response
rates among chronically depressed patients with DPD may represent the difficulty of
treating or changing entrenched personality traits. Moreover, this notion fits particularly
well with the Papakostas (2003) data which found that Avoidant Personality Disorder
was a strong negative predictor of response to treatment. Conversely, if chronically
depressed patients with and without DPD are not distinguishable in terms of treatment
outcome, this would argue against DPD as a distinct diagnostic category and its
usefulness as a prognostic indicator in treatment. To date, there are only scant data on the
impact of DPD on treatment outcome among patients with chronic depression. The only
data relevant to this issue looked at length of treatment and found that patients with
Depressive Personality Disorder spent a mean of 63 months in psychotherapy, which was
more than twice as long as other patients with mild but chronic depression (Phillips et al.,
1998). Thus, consistent with the National Institute on Mental Health directions for future
research on depression vulnerability and resilience, additional research is needed on
personality in order to better understand outcomes and interventions intended to improve
them (NIMH, Basic Behavioral Science Research for Mental Health, 1995).
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Specific Aims:
Our clinical and empirical understanding of depression suggests that effective
treatments are imperative to the amelioration of symptoms and to improve quality of life.
However, establishing treatment efficacy is more difficult for chronic forms of
depression, thus necessitating additional work with this population. Based on past
research demonstrating the impact of Axis-II comorbidity on treatment outcome, it is
expected that chronically depressed patients with comorbid Depressive Personality
Disorder will respond less well to treatment, regardless of modality, than patients without
Depressive Personality Disorder. It is also expected that DPD patients receiving monotreatment (drug alone or psychotherapy alone) will respond less well than DPD patients
receiving combination treatment. This is primarily because DPD is defined by cognitive
symptoms, and to a lesser extent affective symptoms, thus a cognitive and social skills
intervention coupled with pharmacology may provide the most optimum treatment.
Additionally, this was the pattern of results found in the larger treatment trial (Keller et
al., 2000). Since the symptom criteria for DPD are primarily cognitive, it is also
expected that addressing cognition and social problem solving through psychotherapy
will achieve a better treatment response than through a physiologically based intervention
(drug alone).
This study also aims to add information to the existing debate concerning the
nature of Depressive Personality Disorder. Demonstrating the prognostic value of DPD
in the treatment of chronic depression would argue for moving DPD from the appendix to
Axis-II as a bona-fide personality disorder in the next version of the DSM. The proposed
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study will address these issues through a re-analysis of a recent, large trial of 681
chronically depressed patients (Keller et al., 2000).

Primary Aim: The aim of this investigation is to determine whether the presence of
Depressive Personality Disorder will moderate treatment outcome among patients with
chronic forms of depression.

Primary Hypothesis: Patients with chronic depression and a comorbid diagnosis of
Depressive Personality Disorder (DPD) will be less likely to respond to medication,
psychotherapy, or combination treatment compared to patients without comorbid
Depressive Personality Disorder. Specifically, DPD patients will have a significantly
poorer response than non-DPD patients to 3 treatment types:
(1)

12 weeks of treatment with nefazadone (200-600mg flexible dose/daily)

(2)

12 weeks of treatment with Cognitive Behavioral-Analysis System of
Psychotherapy (CBASP)(semi-weekly sessions during weeks 1-4, and weekly
sessions during weeks 5-12)

(3)

12 weeks of combination treatment (Nefazadone + CBASP)

Based on the above hypothesis, we expect to find a significant main effect for DPD
group, with DPD patients showing a significantly poorer response to treatment at week
12 and at last observation carried forward (LOCF) than non-DPD patients across
treatment types, as measured by the Hamilton Rating Scale for Depression (HRSD)
(Hamilton, 1967). We also expect a significant main effect for treatment type (Keller et
al., 2000, reported a statistically significant difference between combination treatment
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and both mono-treatments. There was not a significant difference between monotreatments). We also expect to find a significant interaction between DPD group and
treatment type, with DPD patients in the combination arm performing better than DPD
patients in either mono-treatment group in terms of treatment outcome at week 12 and
LOCF. Moreover, we expect that DPD patients receiving psychotherapy alone will
respond better than DPD patients receiving nefazodone alone.
Methods
Participants
The present study represents a follow-up analysis to a larger trial for the treatment
of chronic depression. This study was previously described in detail by Keller and
colleagues (Keller et al., 2000). In the larger trial, outpatients from 12 academic centers
were screened for inclusion in this study. All eligible subjects met criteria for one of the
following forms of chronic depression:
a) Chronic Major Depression (continuous episode of MDD for 2 years), or
b) Major Depressive Disorder, Single Episode, superimposed on antecedent
Dysthymic Disorder, or
c) Recurrent Major Depressive Disorder with incomplete interepisode recovery
(total continuous illness duration is 2 years and the patient is currently in an
episode of Major Depressive Disorder).
Diagnoses were made according to criteria set forth in the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) (APA, 2000), and obtained using
the Structured Clinical Interview for Axis I DSM-IV Disorders (SCID) (First, Spitzer, &
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Gibbon, 1995). In addition to the diagnostic criteria for chronic depression, several other
conditions were met for patient eligibility (Table 2).
Procedures
The institutional review board at each site approved the study prior to enrolling
subjects. No study specific procedures were conducted until written informed consent
was obtained. Patients underwent a preliminary screening for eligibility according to
inclusion/exclusion criteria (Table 2). Six hundred eighty one (n=681) patients who
remained eligible at the end of a two week evaluation period were randomized in a 1:1:1
ratio for twelve weeks of treatment with nefazadone (n=226), Cognitive BehavioralAnalysis System of Psychotherapy (CBASP) (n=228), or combination treatment (n=227).
Nefazodone: Nefazodone hydrochloride is a synthetically derived
phenylpiperazine antidepressant. It is considered a mixed serotonin antagonist reuptake
inhibitor, with both serotonin and norepinephrine transporter inhibition as well as
antagonism of 5-HT2A and alpha-1-receptors. Nefazodone has demonstrated efficacy in
placebo-controlled trials and in numerous double-blind trials of short-term treatment of
Major Depressive Disorder (Garlow, Owens, & Nemeroff, 2000). Nefazodone was
selected for this trial because, unlike other newer agents, it lacks troublesome side effects,
particularly weight gain and sexual dysfunction.
CBASP (McCullough, 1984): The Cognitive Behavioral Analysis System of
Psychotherapy (CBASP) was specifically designed to target the pathological
characteristics of chronically depressed patients, and has shown promising results in a
small, open trial (McCullough, 1991). At present, it is the only therapy model developed
specifically for the treatment of chronic depression. This approach was developed by
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Table 2. Criteria for study eligibility
Inclusion Criteria
a. Written informed consent.
b. Men or women aged 18-85 years old
c. A score of > 20 on the Hamilton Rating Scale for Depression (HRSD)

Exclusion Criteria
a. Pregnant women or women of child bearing potential who are not using a medically accepted
means of contraception.
b. Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine,
neurologic, or hematologic disease.
c. Clinical or laboratory evidence of hypothyroidism.
d. Uncontrolled seizure disorder.
e. The following DSM-IV diagnoses: 1) organic mental disorders; 2) substance use disorders,
including alcohol, active within the last year or patients with a positive urine drug screen; 3)
schizophrenia; 4) delusional disorder; 5) psychotic disorders; 6) bipolar disorder; 7)
bereavement; 8) adjustment disorder; 9) antisocial personality disorder; 10) panic disorder,
social phobia, GAD or OCD.
f. Patients with psychotic features.
g. Patients who are a serious suicide or homicide risk.
h. Current use of other psychotropic drugs.
i. Patients who have been on a course of Nefazadone during the current episode.
j. Patients previously intolerant to Nefazadone or non-responsive to at least 12-weeks of
cognitive-behavioral psychotherapy.
k. Patients currently in psychotherapy.
l. Patients who have taken an investigational psychotropic drug within the last year.
m. Patients with a positive toxicology screen.
(Keller et al., 2000)
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McCullough and colleagues who suggest that chronically depressed patients are
perceptually disconnected from the environment such that behavioral consequences
cannot inform behavior. Piagetian preoperational functioning in the social-interpersonal
arena maintains the disorder and causes cognitive-emotional-behavioral patterns to
remain on an immature level.
In psychotherapy, patients are taught that their interpersonal behavior has specific
consequences and, in learning to recognize what these consequences are, patients become
perceptually reconnected to their environment and open to feedback from others. This is
achieved through three primary techniques: Situational Analysis, the Interpersonal
Discrimination Exercise, and in-session Behavioral Skill Training/Rehearsal. In
Situational Analysis, the therapist directs the patient’s attention to the effect his/her
behavior is having upon others, and teaches the individual how his/her interpersonal
behavior is affecting the therapist. The Interpersonal Discrimination Exercise shows
patients how the therapist differs in comparative ways to maltreating significant others in
the individual’s life. Behavioral Skill Training/Rehearsal exposes the patient’s
behavioral deficits. Patients learn to inhibit reflexive, hostile reactions and, instead of
reacting impulsively, to wait and see how the situation unfolds and then to react with less
affect. Through practice, patients are able to gain control of their emotional outbursts
and, thus, achieve a more desirable outcome. A more detailed description of CBASP
procedures can be found elsewhere (McCullough, 2003).
Patients randomized to the nefazadone group (n= 226) began an initial dose of
200mg/day (100mg twice a day), with an increase to 300mg/day during the second week.
Thereafter, the dose increased in weekly increments of 100mg, to a maximum daily
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dosage of 600mg. Patients were tapered down to a minimum of 300mg/day if intolerable
side effects occurred. Patients who required a taper below 300mg/day were terminated
from the study and referred to appropriate aftercare. Patients randomized to nefazadone
were seen once weekly for 12 weeks. Visits for medication were limited to 15 to 20
minutes, and psychopharmacologists were not permitted to make formal
psychotherapeutic interventions.
Patients randomized to the Cognitive Behavioral-Analysis System of
Psychotherapy (CBASP) group (n=228) had semi-weekly sessions during weeks 1-4, and
weekly sessions during weeks 5-12. All psychotherapists (Ph.D. or MD degree required)
attended a two day training workshop and met the criteria for mastery of treatment
procedures involved in CBASP, as assessed by evaluation of performance during two
videotaped pilot cases. All psychotherapy cases were videotaped and reviewed weekly
by supervisors.
Patients randomized to the combination treatment group (nefazadone + CBASP)
(n=227) had twice weekly CBASP sessions during weeks 1-4, and weekly sessions
during weeks 5-12. These patients also began an initial regimen of nefazadone
200mg/day, and increased to 300mg/day during the second week. Thereafter, dose was
increase 100mg/day, to a maximum daily dosage of 600mg. Patients were tapered down
to a minimum of 300mg/day if intolerable side effects occurred. Patients who needed to
be tapered below 300mg/day were terminated from the study and referred to appropriate
aftercare.

18
Measures
Diagnosis of chronic depression was assessed using the Structured Clinical
Interview for DSM-IV Axis-I Disorders: Patient Edition (SCID-I/P) (First et al., 1995).
Several studies have demonstrated superior reliability and validity of the SCID
(Williams, Gibbon, & First, 1992; Skre, Onstad, Torgersen, & Kringlen, 1991; Zanarini
& Frankenberg, 2001; Zanarini, Skodol, & Bender, 2000, Basco, Bostic, & Davies, 2000,
Kranzler, Kadden, & Babor, 1996; Shear, Greeno, & Kang, 2000; Steiner, Tebes, &
Sledge, 1995). This clinician-rated SCID proceeds by modules to the different DSM-IV
Axis I disorders. Answers are generally rated on a scale of 1-3 (1= doubtful, 2=
probable/subthreshold, 3= definite/ symptom endorsed), and based on the number of
positive answers, a diagnosis is determined. This measure was administered at the
screening visit to confirm or rule out a diagnosis of chronic depression.
To determine the presence or absence of Depressive Personality Disorder, the
Structured Clinical Interview for DSM-IV Axis-II Personality Disorders (SCID-II) (First,
Gibbon, & Spitzer, 1997) was employed. High reliability and validity of the SCID-II
have been demonstrated in several studies (First, Spitzer, & Gibbon, 1995; Dreessen &
Arntz, 1998; Maffei, Fossati, & Agostoni, 1997; Weiss, Najavits, & Muenz, 1995;
Skodol, Rosnick, & Kellman, 1988). This clinician-rated SCID proceeds by modules to
the different DSM-IV Axis II disorders. Answers are generally rated on a scale of 1-3
(1=doubtful, 2=probable/subthreshold, 3=definite/symptom endorsed), and based on the
number of positive answers, a diagnosis is determined. This measure was also
administered at the screening visit to confirm or rule out a diagnosis of a DPD.
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Depression severity was rated by the Hamilton Rating Scale for Depression
(HRSD) (Hamilton, 1967). The HRSD is the most widely studied instrument for
depression, and its reliability and validity are high (Schwab, Bialon, & Holzer, 1967).
This instrument was completed by the clinician, based on his/her assessment of the
patient's depressive symptoms. The HRSD quantifies the degree of depression in patients
who already have a diagnosis of depressive disorder. Questions focus on depressive
symptoms experienced over the past 7 days. The HRSD is a useful tool for measuring the
progress of a patient during the course of treatment. Answers to questions are rated on a
scale of 0-4 or 0-2, with higher scores indicating more severe pathology. This measure
was administered at screen and baseline to determine patient eligibility, and subsequently
at each clinic visit for enrolled patients to determine changes in depression symptom
severity over 12 weeks.
Results
Prior to conducting statistical analyses, the data were examined for missing cases
for the HRSD baseline, HRSD week 12, and HRSD last observation carried forward
(LOCF) variables. Patients with incomplete or missing data for any of these variables
were discarded from the analysis. Complete HRSD baseline data included 681 patients
(n=681). The primary analyses were based on 484 patients with week 12 HRSD scores,
and secondary analyses were conducted on 647 patients.
Because this sample was selected from a clinical population of chronically
depressed individuals and not from a normal population, HRSD baseline, HRSD week 12,
and HRSD LOCF distributions were examined for problematic skew. Frequency
distribution tables and histograms were created to assess the shape of each distribution
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and detect skew. Problematic skew was further defined as a skew statistic > 1.96.
Because all three variables revealed positive skew, the data were transformed using a
square root transformation in an attempt to improve normality. The mathematical
modification did not produce a skew statistic within the range of + 1.96, thus the original
raw data were accepted for analysis. Due to restrictive entry criteria (HRSD > 20) and a
maximum rating scale total (HRSD = 70), outliers were not found.
Potential confounds for this population have been identified based on previous
literature (Klein & Santiago, 2003). The effects of age, gender, race, marital status and
depression severity were intercorrelated and individually correlated with the dependent
measures (HRSD week 12, HRSD LOCF) to determine influence on treatment outcome.
Depression severity at baseline (HRSD) was significantly correlated with both HRSD
week 12 and HRSD LOCF (r=.121, p <.01, r=.185, p <.01), as was race (r=.092, p < .05,
r=.112, p <.01). When the baseline data are highly correlated with the endpoint data, the
reliability of change scores is significantly problematic (Lord, 1956). Therefore,
difference scores were not used as a dependent measure. While age, gender, and marital
status did not significantly correlate with either outcome variable, previous literature
suggests they may account for some variance in the model (Klein & Santiago, 2003).
Thus the effects of all potential confounds, including age, gender, race, marital status, and
depression severity at baseline were entered as covariates to statistically control for their
effects in the first step of the regression model. Additionally, the effects of other
comorbid personality disorders, other than DPD, were controlled for in order to best
isolate the unique effects of depressive personality. The full correlation matrix can be
found in Table 3.

.917**

.121**

-.005

.092*

.005
-.044

hrsd.99
hrsd.base
gender
race
age
mstatus
-.021

-.017

.122**

.031

.185**

---

.917**

hrsd.99

-.003

.010

.013

.104**

----

.185**

.121**

hrsd.base

.015

.033

.008

----

.104**

.031

-.005

gender

* p < .05, ** p< .01
Note.
hrsd.12 = Hamilton Rating Scale for Depression at week 12
hrsd.99 = Hamilton Rating Scale for Depression at LOCF
hrsd.base = Hamilton Rating Scale for Depression at baseline
mstatus = marital status
The cell sizes vary slightly due to missing data.
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Table 3: Correlations (Pearson r)
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.008
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.180**
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-.021
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Nearly two-thirds of the sample was female with a mean age in the early forties.
The great majority of the sample was Caucasian with less than ten percent being Black,
Asian, Hispanic or other racial or ethnic background. With respect to marital status, most
patients were married, single, or divorced, while less than twelve percent of the sample
reported being separated, widowed, or living together with someone. (Table 4).
To prepare to test the primary hypothesis, patient data was split into those patients
meeting criteria for a comorbid diagnosis of Depressive Personality Disorder and those
patients not meeting criteria for a comorbid diagnosis of Depressive Personality Disorder.
Of the 681 total patients, information on the presence or absence of DPD was not
available for 1 case. This case was discarded, reducing the sample to 680 (n=243 with
DPD, n=437 without DPD). Categorical variables (gender, race, marital status) were
analyzed using chi-square and continuous variables (age, HRSD baseline) were analyzed
using independent sample t-tests. Preliminary analysis found no statistical differences
between groups, suggesting that they were highly similar with respect to basic clinical
and demographic characteristics. In terms of other Axis-II comorbidity, 79% of patients
with DPD (n=193) had an additional Axis-II diagnosis as compared to 27% of patients
without DPD (n=117). This difference was statistically significant (X2 (1) = 55.347,
p<.001). Comparisons on demographic and clinical data for those with versus without
DPD can be found in Table 5. No statistically significant differences were found for any
other clinical variable or demographic characteristic.
It was hypothesized that the presence of comorbid DPD would negatively impact
response to three types of treatment for depression (grouped together), resulting in
significant differences between patients with and without DPD. Treatment outcome was
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Table 4: Demographics for entire sample (n=681)
Age

range: 19-74

mean: 43.3 (10.71)

Male

236 (34.7%)

Female

445 (65.3%)

White
Black
Asian
Hispanic
Other

616 (90.5%)
23 (3.4%)
8 (1.2%)
22 (3.2%)
12 (1.8%)

Single
Married
Widowed
Divorced
Separated
Living with someone

185 (27.2%)
257 (37.7%)
14 (2.1%)
160 (23.5%)
31 (4.6%)
34 (5.0%)

Gender

Race

Marital Status
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Table 5: Demographic and Clinical Characteristics
DPD
(n=243)

no DPD
(n=437)

Baseline HRSD

mean: 27.92
SD:
5.23

mean: 26.24
SD:
4.75

Comorbid PD

193 (79%)
108 (44%)
8 (3%)
50 (21%)
0 (0%)
27 (11%)

117 (27%)*
60 (14%)
2 (0.5%)
45 (10%)
0 (0%)
9 (2%)

range: 19-72
mean: 45.5

range: 20-74
mean: 47

Male
Female

92 (37.9%)
151 (62.1%)

143 (32.7%)
294 (67.3%)

White
Black
Asian
Hispanic
Other

220 (90.5%)
9 (3.7%)
2 (0.8%)
8 (1.2%)
4 (1.6%)

396 (90.6%)
14 (3.2%)
6 (1.4%)
14 (3.2%)
7 (1.6%)

73 (30%)
99 (40.7%)
2 (0.8%)
45 (18.5%)
13 (5.3%)
11 (4.5%)

112 (25.6%)
158 (36.2%)
12 (2.7%)
114 (26.1%)
18 (4.1%)
23 (5.3%)

Avoidant
Dependent
OCPD
Schizotypal
Borderline
Age
Gender
Race

Marital Status
Single
Married
Widowed
Divorced
Separated
Living with someone
* p< .001
Note.
HRSD = Hamilton Rating Scale for Depression
SD = standard deviation
DPD = Depressive Personality Disorder
PD = personality disorder
OCPD = Obsessive Compulsive Personality Disorder
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measured using HRSD week 12 completer data (Table 6). It was further hypothesized
that the presence of comorbid DPD would negatively impact response to treatment within
each treatment arm separately. As mentioned previously, HRSD week 12 completer data
was the primary outcome measure. These hypotheses were simultaneously tested using a
mixed 2 x 3 factorial ANCOVA design. This analysis was repeated using an alternate
outcome variable, HRSD last observation carried forward (LOCF) (baseline + at least one
additional treatment visit)(Table 7).
Results of the primary analysis found no significant main effect for DPD,
suggesting that there is not a significant difference between patients with comorbid DPD
and patients without comorbid DPD in terms of treatment outcome at week 12 (F (2,469)
= 0.151, p = .860) (Figure 1). As expected, there was a significant main effect for
treatment group (published previously in Keller et al., 2000). Results from the original
study revealed a significant difference between combination treatment and both
monotherapies, with combination treatment reducing depression severity at week 12
significantly more than either therapy alone (F (2,469) = 9.409, p = .00). There was no
significant difference detected between drug alone and psychotherapy alone. Further,
there was no significant interaction between DPD and treatment group, which suggests
that treatment outcome among patients with and without DPD is not significantly
different depending upon treatment type (F (4,469) = 0.612, p = .654) (Figure 2, 3, 4, 5;
Table 8). When re-analyzed without controlling for the effects of other personality
disorders, the overall statistical outcomes remained the same. Therefore, the hypothesis
that patients with a comorbid diagnosis of DPD would differentially respond to treatment,
as a whole and/or within each treatment arm, was not supported. Thus, in this sample,
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Table 6: Descriptive Data for HRSD Outcome at Week 12
______________

n

Mean HRSD

SD

No DPD

316 (65%)

12.91

8.76

DPD

168 (35%)

13.07

9.70

No DPD

97 (63%)

14.39

8.66

DPD

57 (37%)

15.00

10.59

No DPD

104 (66%)

14.79

9.27

DPD

53 (34%)

14.51

10.68

No DPD

115 (66%)

9.79

7.47

DPD

58 (34%)

9.84

6.73

Overall (n=484)

Nefazodone (n=154)

Psychotherapy (CBASP) (n=157)

Combination (n=173)

Note.
HRSD = Hamilton Rating Scale for Depression
SD = standard deviation
DPD = Depressive Personality Disorder
CBASP = Cognitive Behavioral Analysis System of Psychotherapy
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Table 7: Descriptive Data for HRSD Outcome at Last Observation Carried Forward
n

Mean HRSD

SD

Overall (n=647)
No DPD

412 (64%)

14.01

9.48

DPD

235 (36%)

14.43

10.35

No DPD

132 (62%)

15.11

9.31

DPD

82 (38%)

16.72

10.83

Nefazodone (n=214)

Psychotherapy (CBASP) (n=215)
No DPD

140 (65%)

15.54

9.51

DPD

75 (35%)

16.16

10.81

No DPD

140 (64%)

11.29

9.09

DPD

78 (36%)

10.35

8.02

Combination (n=218)

Note.
HRSD = Hamilton Rating Scale for Depression
SD = standard deviation
DPD = Depressive Personality Disorder
CBASP = Cognitive Behavioral Analysis System of Psychotherapy
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Table 8: Summary of 2 x 3 factorial ANCOVA for DPD at week 12
F

partial η2

Variable

df

HRSD baseline

1

9.958**

.021

Race

1

2.697

.006

Age

1

.169

.000

Gender

1

.127

.000

Marital status

1

1.110

.002

Comorbid PD

1

3.893*

.008

Treatment group

2

9.409**

.039

DPD

2

.151

.001

Treatment group x
DPD

4

.612

.005

* p < .05, ** p< .01
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression
partial η2 = partial eta squared
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Treatment Outcome at Week 12
Mean HRSD at Week 12

20
15

12.91

13.07
No DPD

10

DPD

5
0
No DPD

DPD

Com orbid diagnosis

Figure 1: Treatment Outcome at Week 12 (HRSD)
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression
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Nefazodone Outcome at Week 12
Mean HRSD at Week 12

20
15

14.39

15
No DPD

10

DPD

5
0
No DPD

DPD

Com orbid diagnosis

Figure 2: Nefazodone Outcome at Week 12 (HRSD)
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression
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Mean HRSD at Week 12

Psychotherapy (CBASP) Outcome at
Week 12
20
15

14.79

14.51
No DPD

10

DPD

5
0
No DPD

DPD

Com orbid diagnosis

Figure 3: Psychotherapy (CBASP) Outcome at Week 12 (HRSD)
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression
CBASP = Cognitive Behavioral Analysis System of Psychotherapy
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Combination Outcome at Week 12
Mean HRSD at Week 12

20
15
10

9.79

9.84

No DPD
DPD

5
0
No DPD

DPD

Com orbid diagnosis

Figure 4: Combination Outcome at Week 12 (HRSD)
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression

33

Nefazodone

Psychotherapy

9.79

9.84

DPD

14.51

14.79

15

No DPD
14.39

Mean HRSD at Week 12

Outcome by Treatment Arm at Week 12
20
18
16
14
12
10
8
6
4
2
0

Combination

Treatment Group

Figure 5: Outcome by Treatment Arm at Week 12
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression
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the presence of DPD was not a prognostic indicator of worse treatment outcome for
patients with chronic depression as measured by the HRSD at week 12.
Results of the secondary analysis, in which the HRSD last observation carried
forward (LOCF) was examined as the dependent measure, were similar to the primary
analysis. There was no significant main effect for DPD suggesting that there is not a
significant difference between patients with comorbid DPD and patients without
comorbid DPD in terms of treatment outcome at LOCF (F (2,632) = 0.073, p =
.930)(Figure 6). As expected, there was a significant main effect for treatment group
(published previously in Keller et al., 2000). Results from the original study revealed a
significant difference between combination treatment and both monotherapies, with
combination treatment reducing depression severity at last observation carried forward
(LOCF) significantly more than either therapy alone (F (2,632) = 11.730, p = .00). There
was no significant difference detected between drug alone and psychotherapy alone.
Further, there was no significant interaction between DPD and treatment group, which
suggests that treatment outcome among patients with and without DPD is not
significantly different depending upon treatment type (F (4,632) = 0.477, p = .753)
(Figure 7, 8, 9, 10; Table 9). When re-analyzed without controlling for the effects of
other personality disorders, the overall statistical outcomes remained the same. As
before, the hypothesis that patients with a comorbid diagnosis of DPD would
differentially respond to treatment, as a whole and/or within each treatment arm, was not
supported. Thus, in this sample, the presence of DPD was not a prognostic indicator of
worse treatment outcome for patients with chronic depression as measured by the HRSD
last observation carried forward (LOCF).
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Table 9: Summary of 2 x 3 factorial ANCOVA for DPD at LOCF
F

partial η2

Variable

df

HRSD baseline

1

29.124**

.044

Race

1

8.621*

.013

Age

1

.033

.000

Gender

1

.316

.001

Marital status

1

.421

.001

Comorbid PD

1

1.810

.003

Treatment group

2

11.730**

.036

DPD

2

.073

.000

Treatment group x
DPD

4

.477

.003

* p < .01, ** p< .001
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression
partial η2 = partial eta squared
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Mean HRSD at LOCF

Treatment Outcome at Last
Observation Carried Forward(LOCF)
20
15

14.01

14.43
No DPD

10

DPD

5
0
No DPD

DPD

Com orbid diagnosis

Figure 6: Treatment Outcome at LOCF (HRSD)
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression
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Nefazodone Outcome at LOCF

Mean HRSD at LOCF

20
15.12

16.72

15
No DPD

10

DPD

5
0
No DPD

DPD

Com orbid diagnosis

Figure 7: Nefazodone Outcome at Last Observation Carried Forward (LOCF)
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression
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Mean HRSD at LOCF

Psychotherapy (CBASP) Outcome at
LOCF
20

15.54

16.16

15
No DPD

10

DPD

5
0
No DPD

DPD

Com orbid diagnosis

Figure 8: Psychotherapy (CBASP) Outcome at Last Observation Carried Forward
(LOCF)
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression
CBASP = Cognitive Behavioral Analysis System of Psychotherapy
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Combination Outcome at LOCF

Mean HRSD at LOCF

20
15

11.29

10.36

10

No DPD
DPD

5
0
No DPD

DPD

Com orbid diagnosis

Figure 9: Combination Outcome at Last Observation Carried Forward (LOCF)
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression
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Outcome by Treatment Arm at LOCF
20
16
14
12

10.36

4

DPD
11.29

16.16

6

15.54

8

16.72

No DPD

10
15.11

Mean HRSD at LOCF

18

2
0
Nefazodone

Psychotherapy

Combination

Treatment Group

Figure 10: Outcome by Treatment Arm at Last Observation Carried Forward (LOCF)
Note.
DPD = Depressive Personality Disorder
HRSD = Hamilton Rating Scale for Depression
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These unanticipated results prompted further investigation of the impact of
personality disorders, other than DPD, to determine which, if any, would show
differential response to treatment as suggested by the pathoplasticity model of personality
and depression (Klein et al., 2002). However, small numbers of positive comorbid
diagnoses for dependent personality disorder (n=10), schizotypal personality disorder
(n=0), and subthreshold borderline personality disorder (n=36) prohibited analyses due to
lack of power to detect effects.
A mixed 2 x 3 factorial ANCOVA was performed for Avoidant Personality
Disorder (APD). Twenty five percent of patients (n=168) were positively diagnosed with
comorbid APD as compared to 75% of patients (n=512) who were not. There was no
significant main effect for APD suggesting that there is not a significant difference
between patients with comorbid APD and patients without comorbid APD in terms of
treatment outcome at week 12 (F, (2,469) = 1.215, p = .298) or at LOCF (F (2,632) =
0.243, p = .785). Likewise, there was no significant interaction between APD and
treatment group for either dependent measure, which suggests that treatment outcome
among patients with and without APD is not significantly different depending upon
treatment type (HRSD week 12: F (4,469) = 1.298, p = .270; HRSD LOCF: F (4,632) =
.577, p = .680). When re-analyzed without controlling for the effects of other personality
disorders, the overall statistical outcomes remained the same. Therefore, the presence of
APD was also not a prognostic indicator of worse treatment outcome for patients with
chronic depression.
A mixed 2 x 3 factorial ANCOVA was also performed for Obsessive Compulsive
Personality Disorder (OCPD). Fourteen percent of patients (n=95) were positively
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diagnosed with comorbid OCPD as compared to 86% of patients (n=584) who were not.
There was no significant main effect for OCPD, suggesting that there is not a significant
difference between patients with comorbid OCPD and patients without comorbid OCPD
in terms of treatment outcome at week 12 (F, (2,469) = .268, p = .765) or at LOCF (F
(2,631) = 0.077, p = .926). Similarly, there was no significant interaction between OCPD
and treatment group for either dependent measure, which suggests that treatment outcome
among patients with and without OCPD is not significantly different depending upon
treatment type (HRSD week 12: F (4,469) = .577, p = .680; HRSD LOCF: F (4,631) =
.167, p = .955). When re-analyzed without controlling for the effects of other personality
disorders, the overall statistical outcomes were similar. As before, the presence of OCPD
was not predictive of worse treatment outcome for patients in this sample.
In a final analysis, the presence of any personality disorder, regardless of type,
was examined in terms of impact on treatment outcome at week 12 and LOCF using a
series of mixed 2 x 3 factorial ANCOVAs. At week 12, there was a significant main
effect for personality disorder (F(1,473) = 3.894, p < .05). Contrary to our predictions,
those with a personality disorder actually had lower HRSD scores at week 12. (Table 10;
Figure 11). However, there was no significant interaction which demonstrates that this
difference does not depend on treatment type (F(2,473) = .882, p = .415). No significant
findings were revealed at LOCF.
Discussion
The fourth edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) included a provisional set of criteria placed in Appendix B. Here, Depressive
Personality Disorder (DPD) was included as a diagnostic category needing further
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Table 10: Summary of 2 x 3 factorial ANCOVA for any PD at week 12
partial η2

Variable

df

F

HRSD baseline

1

11.113*

.023

Race

1

2.567

.005

Age

1

.153

.000

Gender

1

.107

.000

Marital status

1

1.445

.003

Treatment group

2

17.677**

.070

PD

2

3.894*

.008

Treatment group x
PD

4

.882

.004

* p < .05, ** p< .01
Note.
PD = Personality Disorder
HRSD = Hamilton Rating Scale for Depression
partial η2 = partial eta squared
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Mean HRSD at Week 12

Impact of Personality Disorder at
Week 12
20
15

13.76

11.92
No PD

10

PD

5
0
No PD

PD

Com orbid diagnosis

Figure 11: Impact of Personality Disorder on Treatment Outcome at week 12
Note.
PD = Personality Disorder
HRSD = Hamilton Rating Scale for Depression
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evaluation. A large amount of theory has been generated on the validity of DPD which
has ignited discussion about whether DPD should be allied with mood or personality
disorders. However, there is little empirical literature available to aid in its evaluation.
The primary aim of this research was to determine whether patients with chronic
depression and a comorbid diagnosis of DPD would respond differentially to three
treatment types as compared to chronic patients without comorbid DPD. This aim has
implications not only for the treatment of chronic depression, but for the validity of the
depressive personality diagnosis. If DPD should stymie treatment response as
hypothesized, this would bolster support for this diagnosis which is awaiting further data.
Results of these analyses indicated that the presence of DPD did not moderate
treatment outcome at week 12 or at last observation carried forward (LOCF) as predicted.
This was the case both for treatment as a whole as well as within each treatment arm
individually. Moreover, in a series of ancillary analyses, neither comorbid Avoidant
Personality Disorder (APD) or comorbid Obsessive Compulsive Personality Disorder
(OCPD) served as a prognostic indicator of worse treatment outcome at week 12 or
LOCF. Taken together, these findings suggest that comorbid personality abnormalities
may not be a clinically useful indicator of worse treatment outcome, at least among
patients with chronic forms of depression in this sample. Notably, in one analysis, the
presence of any one personality disorder actually predicted a better response after 12
weeks of treatment with either nefazodone, targeted psychotherapy, or combination
treatment.
One explanation for this result may lie in the findings of other empirical work
examining treatment effects for personality disorders. Several investigators have found
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that antidepressants may be helpful in the treatment of personality disorders regardless of
change in depression (Fava, Farabaugh, Sickinger, Wright, Alpert, Sonawalla,
Nierenberg, & Worthington, 2002; Kapfhammer & Hippius, 1998; Markovitz, Calabrese,
Schultz, & Meltzer, 1991). Treatment, in any modality, may be accompanied by
significant changes in behaviors and attitudes that are a part of personality disorders and
independent of changes in depression severity. In this study, psychotherapy (CBASP)
was designed specifically to target such issues. Moreover, Shea and colleagues have
suggested that the added distress of depression among patients with personality disorders
may actually serve as a motivator to comply with treatment and modify the behaviors that
contribute to their difficulties (Shea et al., 1992).
Another possibility is that patients with personality disorders may have had a
different illness than patients without personality disorders. Those with the comorbid
conditions may have a form of depression that is secondary to the personality disorder
and more amenable to clinical intervention. On the other hand, those with a primary
diagnosis of chronic depression that was not secondary to a personality disturbance
maybe more refractory. Finally, there is also the possibility that those with a personality
disorder were more likely to negatively distort the reports of their history of depression
and, in fact, did not have as severe a mood disturbance as the pure, chronically depressed
group.
While the pathoplasticity model of personality and depression may predict that
DPD would negatively impact treatment response as compared to patients without the
comorbid diagnosis, there is also a body of literature to suggest that the presence of
comorbid personality disorders does not influence response to treatment (Fava et al.,

47
1994; Newman et al., 2000). Thus, the results from this research lend support to this
evidence base. However, it is important to note that there is a relative dearth of empirical
information pertaining to treatment outcomes among patients with chronic forms of
depression and comorbid personality disorders. The majority of published studies which
have examined the impact of personality disorders have been performed on samples of
acutely depressed patients (McDermut & Zimmerman, 1998; Sato et al., 1994; Shea et
al., 1992; Shea et al., 1990). As distinguished earlier in the paper, chronic forms of
depression may represent a distinct subset of patients. Thus, it is important to consider
that the pathoplastic effects of personality disorders may not apply to persistent, severe
forms of depression.
Secondly, it is possible that the chronic and severe nature of this sample led to
mood state effects on the assessment of personality disorder. That is, ratings of
personality disorders could have been distorted by the depressive episode. Thus,
personality abnormalities may be concomitant with chronic depression and return only to
nonsymptomatic levels after recovery (Klien et al., 2002). As discussed by Klein and
colleagues, mood state effects are particularly problematic when trying to disentangle
comorbid diagnoses. It is complicated to determine whether the comorbid problem is a
consequence of the mood state or if it existed as an independent, pre-morbid condition.
In the former case, it would make sense that the alleviation of mood symptoms would
also alleviate other comorbid symptoms, such as those recognized and diagnosed as
personality disorders. If it were the case that the personality abnormality existed outside
of the depressive episode, then treatment for the mood disorder would not be expected to
ameliorate the pre-morbid personality symptoms. In our sample, it was unknown
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whether or not the symptoms of depressive personality existed prior to, and/or were
independent of, the depressive episode. The results of this study, interestingly, suggest
that whether or not the personality disorder was pre-morbid or existed as a consequence
of mood state, treatment of the mood disorder was not hampered by the presence of DPD
or any of the other personality disorders assessed.
Third, because DPD presently resides in the appendix of the DSM-IV as a
condition requiring further study, there is relatively little empirical data to determine
whether or not it should be construed as a bona-fide personality disorder. Because the
clinical symptomatology required for a diagnosis of DPD greatly overlap with those
required to diagnose Dysthymic Disorder, there has been large debate in the recent
psychological and psychiatric literature about the validity of DPD as a distinct condition
(Hirschfeld & Holzer, 1994; Clark & Watson, 1999; Bagby & Ryder, 1999; Huprich,
2001). In this sample, DPD was considered a personality disorder which was separate
from the mood episode. However, as mentioned previously, missing pre-morbid and/or
post-treatment assessment prevents any reliable conclusion to be drawn about the true
nature of DPD.
Strengths of the current study
There are a number of strengths of the present study that warrant recognition.
First, the sample selected for this study was based on rigorous recruitment at twelve
clinical sites in the United States. Not only did this large sample size include patients
from diverse geographic locations, it contributed to very high-power research. Second,
careful diagnoses were captured by trained clinicians using structured interviews. Such
strict assessment was used both in screening patients for eligibility as well as ensuring a
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high rate of inter-rater reliability and, thus, a high level of internal validity. Moreover,
clinical outcomes were assessed at each clinic visit using the Hamilton Rating Scale for
Depression, the mostly widely recognized instrument for detecting depressive
symptomology and severity among severely depressed patients.
Third, two different outcome variables were employed for analysis in this study.
Data evaluated from week 12 completer patients permitted examination of treatment
outcomes among individuals who received the same course of treatment. Conversely,
evaluation of patients who terminated early from the study allowed for comparisons to be
made to those who completed, and to assess their differential outcomes. Further,
including last observation carried forward (LOCF) data ensured that all patient data,
regardless of treatment course, were considered for analysis and not discarded.
Lastly, this clinical trial was conducted using highly manualized treatment
approaches. This helped guarantee consistent treatment delivery across clinical site and
maximized the internal validity of the research. Further, all study clinicians assessing
patients, at any time-point, were required to have a Ph.D. or M.D. degree.
Psychotherapists involved in the Cognitive Behavioral System Analysis of Psychotherapy
(CBASP) attended a mandatory, two day training workshop and met the criteria for
mastery of treatment procedures. This was assessed through evaluation of performance
during two videotaped pilot cases, and all subsequent psychotherapy cases were
videotaped and reviewed weekly by supervisors.
Limitations of the current study
There are several limitations to the current research to consider. First, the
demographics of the sample were overwhelmingly comprised of Caucasian individuals
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(90%) and nearly two thirds (65.3%) of patients were female. Although a more racially
diverse sample would improve the generalizability of the results, the gender ratio closely
approximates epidemiological estimates of depression in community samples (Kessler et
al., 1994; Kornstein, 1997). With respect to inclusion criteria for study entry, patients
with severe borderline personality disorder and/or antisocial personality disorder were
excluded, as were acutely suicidal patients. These ineligible patients may have provided
important, clinically relevant data when considering a cohort of individuals with chronic
depression. In addition, some Axis-II diagnoses were never assessed including paranoid,
schizoid, histrionic, and narcissistic personality disorders. Thus, patients with these
personality abnormalities may have been present in this sample, yet remained
unaccounted for.
Secondly, inclusion criteria for the trial required the presence of “chronic”
depression; however, patients with three types of depression were admitted for study:
patients with a pre-existing Dysthymic Disorder and a superimposed major depressive
episode, patients in a current major depressive episode, and patients with residual
symptoms of depression. While all patients were similar in terms of episode course, this
complicated the moderation analysis of comorbid DPD such that all primary diagnoses
were amalgamated. While this is considered a limitation, it should be noted that no
single definition of chronic depression exists in our current nosology; that is, the DSM-IV
regards several depressions as having the longitudinal course specifier of chronicity, as
opposed to one, distinct diagnosis of chronic depression.
Third, assessment of DPD was captured only at the screen and baseline visits.
While this information is relevant and required for the present research, there is no way to
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determine whether personality pathology existed independent of, and/or prior to, the
mood episode. As mentioned previously, it is unknown whether the presence of DPD
was a distinct Axis-II condition or if it was simply a concomitant mood state effect.
Further, because DPD was not reassessed at treatment endpoint, it is not possible to
decipher whether the symptoms of depressive personality were affected by treatment.
Future directions
The limitations of the present research have provided a number of pathways for
future research. Beginning with the first limitation, it would be potentially useful to
recruit subjects that are more demographically representative of the overall population.
This would not only increase the external validity of the results, but would provide useful
clinical data for effectively treating diverse populations.
Second, given that various personality disorders were either excluded or were not
assessed, it is critical that future research aim to more carefully account for Axis-II
comorbidity. Conventions should be implemented regarding the types of personality
pathology that will be allowed for study, and these patients should represent a collective
sub-sample. This would ensure that Axis-II pathology is captured and evaluated
properly, thereby increasing the validity of the research and the conclusions that are
drawn.
Third, because several types of mood disorders (double depression, chronic
MDD, MDD in incomplete remission) were pooled into one group (chronic depression)
based only on longitudinal course, it seems necessary and prudent to research the various
types of chronic depression separately or in head-to-head comparison trials. For example,
a diagnosis of “double depression” is warranted when Dysthymic Disorder has been
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present for at least 2 years and is subsequently followed by a superimposed major
depressive episode. This means that the original disorder is characterized by an early,
insidious onset, while “MDD chronic” is a full-blown and severe mood episode, while
patients with MDD in incomplete episode recovery are, presumably, in the maintenance
phase of treatment. Thus, the problematic admixture of this sample may be reduced
through more diagnostically homogeneous samples to allow for greater specificity in
measurement, treatment, and outcome analysis associated with these various forms of
depression.
Fourth, because we can draw only tentative conclusions about the impact of DPD
on treatment outcome due to unavailable pre-morbid data, there is a critical need for
alternate research designs such that personality and depression are adequately
distinguished from one another. This is the only way to be certain that the personality
disorder being studied is, in fact, a personality disorder and not a concomitant mood state
bias. One way this could be tested is through cross-sectional studies of patients in
remission, or through longitudinal studies assessing patients when they are in an episode
and again after they have recovered. If personality abnormalities persist after remission,
it would suggest that they are trait markers rather than complications of the depressed
state. To our knowledge, only 2 studies have tested personality measures in depressed
individuals before and after a major depressive episode. However, each of these projects
aimed to examine personality traits (neuroticism/extraversion) and not personality
disorders (Kendler, Neale, Kessler, Heath, & Eaves, 1993; Shea, Leon, Mueller,
Solomon, Warshaw, & Keller, 1996).
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Potentially useful data could also be garnered from family, twin, and adoption
studies. Demonstrating that never depressed relatives of patients with mood disorders
have higher levels of personality disorder than healthy relatives of controls would provide
some support for personality pathology existing independent of mood state. Further
support could be offered if relatives of never depressed patients with personality
abnormalities had an elevated rate of mood disorders (Klein, 2002). The most
compelling approach, however, is to conduct longitudinal studies of individuals with no
prior history of mood disorder and trace the development and impact of personality
vulnerabilities as the patient waxes and wanes through mood episodes. Thus, future
research should seek to examine more closely pre-morbid personality to make certain
personality pathology existed prior to the mood episode, if it is concomitantly present as
a mood state effect, or if it exists as a consequence of the mood episode. If these groups
could be disentangled, then followed through treatment, we would have a better idea of
the clinical prognostic value of personality disorder at the time of treatment.
Conclusion
Chronic depression, in one form or another, accounts for about twenty percent of
all depression (Mueller, Keller, & Leon, 1996). In all cases, including this sample, the
full syndrome of major depression exists for 2 years or longer which means that these
patients suffer from continuous emotional and functional impairment. Moreover, high
rates of comorbid Axis-II disorders are frequently seen, thus significant adaptation is
required on the part of patients and their families to cope with the illness.
Given that chronic forms of depression are often associated with personality
disorders and frequently result in poorer clinical outcomes, investigation into the impact
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of Axis-II disorders on treatment outcome is highly warranted. The purpose of this study
was to examine the effects of DPD on treatment outcome for patients with chronic
depression. In this sample, the presence of comorbid DPD did not impact response to
any of the three treatment types. Moreover, the presence of Avoidant Personality
Disorder and Obsessive Compulsive Personality Disorder in particular, or any of several
personality disorders as a general comorbid condition, did not predict worse treatment
outcome. While these empirical findings were not significant in terms of differential
response to treatment, the clinical implications are highly important. That is, among
patients with persistent forms of depression, a comorbid personality disorder diagnosis
did not make treatment for these patients more difficult. While it is often assumed that
patients with personality disorders are challenging to treat, the findings from this work
suggest that they responded as well as patients without co-existing personality disorder.
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